Sino Biopharmaceutical Limited · HKEX:1177
Sino Biopharmaceutical — H1 2024 Earnings Presentation
22 slides from Sino Biopharmaceutical's earnings presentation, Aug 13, 2024
Slide 1: 2024 Interim Results Announcement & Investor Day
FP EY) See IA) SINO BIOPHARMACEUTICAL LIMITED ARE=(K4S/Stock Code: 1177 HK 2024F Palak SRAaH 2024 Interim Results Announcement & Investor Day 2024.8.13 itm
Slide 2: Wea ES St Azitt
ih Wea ES St Azitt
Slide 3: Interim results highlights
Weir: CESARE, PMR FULA (ARi& 1270) WA WAS AAU SNon-HKFRSIAB FA +14.0% 2023H1 2024H1 2023H1 2024H1 2023H1 2024H1 SE: 1) SiSRNon-HKFRSIAS FF: AAAS LEA, AAMAS TRREMEBRMARZE IR, FEEITESARED Bi EELMERASS | 3 2) CHER S AEP BIC AILS Bs
Slide 4: Non-HKFRS reconciliation
i5=Non-HKFRSISSVSAS (ARRTB (270) 2024H1 2023H1 aE FETFSAassanoRA 30.2 12.6 +139.7% PAI4EWS ZIRT SAasae oR -16.1 1.3 NORECAR-RABAAMBURSIA JOB ARIAS AE) 0.9 21 BAP RARZARMERAR RE 0.5 -0.9 TAAL AZATMERT, HR -0.1 -0.6 FR MRTHRS ABD: ABER 0.0 01 IC ae bc) AR -0.0 08 SONOBMANBAZTESMIR ZAIN - -0.5 ER AD AR
Slide 5: Revenue and R&D investment
RASeE: BRWUMSKR, KREWE, ALBERS SeA (ABRm 1270) BERS e” BrRe os RE EE A ate mainte rT 200{Z+ a eee 30% + nema ARI Sl HERR PRIN ALTT 65148: Ss -HBERRRRA RD RAT crs Fal 180% (5) 1SIZTE CNY gy 1.95% sett AKEITBRIEEL MTT EEA, LAER LE 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ; 2023 H1 2024H1
Slide 6: Revenue composition and innovative products
Hae: RAMA, RRMA, ARABS, WOF# (Giaibeehi CE HA HSLAB BURT aid AREA aa SNE REDAR iA ait FHA AEE E Bee 24.0 26.3 42% 41% AOE +e so BRIREFCABIRXN wT ED7TFFZEA (ABRiB (2:70) fae) 16.0% 16:8% 16.3% 16.2% 76% mE 25.8 72% 24% 2019 2020 FE: 1) 2024FHIAIRA BAIL SLLIA 93.4%, (SIPS PIERG, HAAR /SES RE Re 2021 2
Slide 7: Innovative product launch timeline
Cai mRe: RES RES, BRB RHA BRE OE aa KA Skt 40% RieLO MARAT TQB3616 (CDK2/4/6iD 7) Zgh© HBEKEDARS TQ05105 (JAK/ROCK#éil fl) RHE® BRS ERS RSS BAARMAFVila Ey) ARDENT HIS. — SR, — ERR ann 2024 2025 2026 FR/ {ti DEAS AABAER f- 4 : SF eA PRE —S Ae RSBR C=ATEARS. Saws
Slide 8: D-1553 Garsorasib KRAS G12C
Cue ane — Fit 2025 Eas m: A D-1553 (Garsorasib, KRAS G12CHP#I#I)) #AEFIC, BebisSa *RSONmERan PSR: 2023088, wt MISGEFIEAAISD-1 5537 ABARAT, GEAR, EPRICE. IR, BACAR D SALE, IEAAIEN REP ELPA PBA BLN es. RRR: BABS SSA HUA IGPRSINERAY KRAS G12C Hill S5SHP2, MEK BAIA BIAS RA EFS IGPRETAR RIGA IFRS, SRSA t
Slide 9: TQB3616 CDK2/4/6 inhibitor
UF Gn keee — Fait2025 LPS: TQB3616 (CDK2/4/6}DEI#) AEALATHR+/HER-FLERERAIBICTT IX TQB36 © RMA o FARE © RES SICDK 2AM BRED IEBERER, TQB3616 ORR InPRRIAGER TR, TQB3616 CDK2/4/ 6} 57) BARR FOORERY, BY KFAKBA BLAU (=e HRLERA, SIF BEATER RACDK4/6 25 HBRURITYIF2024 CSCO) FOUR PRAUAIS (SLE Ht BIC HR+/HER-
Slide 10: HER2 cancer market and TQB2102
CUR coe — FRt20255 bse: HZRSREVAVARSEASALh, “AHA” RRGRHHER2ATEPLER ES Fike: SERA” reine oy acer ~ ORFS ME ith SL, HOR HER2 (Bt REPL BRE tomer 15-20% samsaenncy "A 2022, SERRE os we ee as arene. wn 23054” HER2SAPEDGHAPL BRE 73 20228, PEAR HERQDBUERLERR «RFRA PRI SRA le ar Fi 365A?) Par “an (cas) BAER
Slide 11: Breast cancer treatment portfolio
AGE: -SNKnasRetia, MARES Fina GLb i FEAK® FAERIE FaEK® Unto eaey ER ® (HES) HR+/HER2- FR ~65% BO HEB Op ' e ve aeale RER® STH "7 es BiHO -RiBibER RER® SHR Bi8@ Rb ees TQB3616 (CDK2/4/6i) #1) ETBERIS WAS bbs TQB2102 (HER2WUAADC)” IER TQB2930 (HER23in) IA FRSC Erp SP BE+PD-1/PD-L1 Hg 2S (ABASSE) Bente
Slide 12: Upcoming approvals and launches
GUAT ake — PRT 2025 SF SHAE FGRR : RE REe+ ARGS (PD-L1) MitRit-SSwwe. —=AFShike Brat_bre I ill} oT Seep gas iSME oan SRA oe FARES 56) A Hy ea ree 20242545 20234618 ESF SARs PD-L1 PRT 2025 202452 Sa PD-L1 PRT 2025 2024578 NSCLCBMGIT atts PD-L1 Fait 2026 Ft 2024 ae PD-1 PRT 2026%F Wt 20245E BARA end P
Slide 13: Business development deals
BD: Seeker ie See BSR AAR A eR AR Zongertinib 20244F4 (HER23ef2 tH) SHUMEBNE A LMMEGTE (aE {SEE AUAISRRE HERZ BI 764532 (BRIEF 2088) 2S (DLL3/CD3US Set BEEHET, ETS a THREES) imu WGERUEB + 2ERaE/| mans (NSCLC) WCDI ATA, + 185 E/)4H83 (NSCLC) AYER F2a4 6 DLL Ae PETEECAIIA DEFER UII apy iI cores we Sun
Slide 14: BESS mar
ih BESS 5 mar
Slide 15: SORA Rie, TH. . BADE da
OR Fr SORA Rie, TH. . BADE da Spices BM IRAE)
Slide 16: Segment results
oF: SECHSRRGSTBERIIISAROEIG, EERIE ren pice en TRAD) (ARB (270) PAZEWSzZ SPR, HEA RBAMNESED s2ia Sh) 81.8% 82.1% GciGHE=, PRERIBRIBTt ll FA SCRA OOOOLMRRISE, MERU +t 2023H1 2024H1 16
Slide 17: Segment results and margins
ES: St. SMtSae L ARO RGE, Waa EA (ARRih 1270) iE (=) SRSA RKAR FEA RE ce SEE HE > 49.2% CRuRE ° 47.3% 45.0% eee 43.6% 43.1% 2021 2022 ©2023 '2023H1 2024H1 saat aie. +Eowew Agen CRMARSE, ep mes oumewmmpe | | 2019 2020 2021 2022 2023 | 2023H1 2024H1 2021 2022 = =—.2023-:12023H1 2024H1 HSBE REE HRBE RR
Slide 18: Therapeutic area products
Atay wait: Ua MEA, OA mAh iss XK 2024 H1 #f_Erb*ia EL® 1K, RAMP RERE, KA Lassen fSTASRT eae MaereN—Ser Rists® 1SCURES, FARES ALKADBIAIATTAVALK smilie «BARES ARMRERSIRSPS ESE) RBEREROIATT Rihe® 1ONRES, ASSSLFROS 1 PETERS SABE BOReSnsekEe Teeth Mabie ATNE eas QMO BP a=, GLP-13ee aR, Pak AZ ASIN E SR R
Slide 19: Segment performance
GUeian: $H415%, REO, SCWMRBARIEKK (ARB (270) Ba aA? +14.8% 23 5F prea RRS EE EINE a) AO STOUR RORS _. & BEHG-csF =~ PRS EO 2023H1 2024H1 3E: 1) Gir mama E Mss 19
Slide 20: Segment performance
QUOTFER: HK 15%, EARESEINERA, Saale A FREINBRIENS A. (ARB (270) Ba aA? +14.8% TOURS 125006 BLAFROSI AREERAU oar smh REAR ATE Dt eed q He RIO STE Cini araz, SRIECATAALKI GLP-1 EFL, TEE MaRS FB aL AZ ER a RET 3 Peper | ZB® EHO tee 2023H1 2024H1 3E: 1) Gir mama E Mss 20
Slide 21: &, (plese yen
&, (plese yen et Ls bey Lath ik SREOREARAR (AER {Z70) AeEStIESILA FAUT RRR OS IES PRIS EMC fame fsFiAe)_bih10+(p Hes ote if OSL ntlesin \omestat@n=” P/E 2023H1 2024H1 3E: 1) LeEAAIASE et ,
Slide 22: Top 30 innovative pipeline products
FARRE: SRM, Wa mB LHMe, WANS eMUeeK da Bi ae tele el ie FOR HUL® (RPRE) FUEM® (Abe) {Z328F® (VLMBAISa) FBO (SRBRE) ZBE® QRFRSN) TDIO1 (ROCK2#D BNF) FASO (MET) 7QC2731 (TSLPERH) SZ® HZSei) TCR1672 (P2X3#54l) REO (HREM) TQC3721 (PDE3/4it04 4) Garsorasib (KRAS G12CiD#3#) TQH2722 (IL-4Rastti) TQB3616 (C
Sino Biopharmaceutical — H1 2024 Earnings Presentation on 6ix